FIELD: medicine; pharmaceuticals.
SUBSTANCE: invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof. Also disclosed is a pharmaceutical composition for treating a VT-mediated disorder based on said compound or a salt thereof.
(I).
EFFECT: technical result is obtaining a novel compound and a pharmaceutical composition based thereon, which can be used in medicine for treating a BTK-mediated disorder selected from an immune disorder, cancer, cardiovascular diseases, viral infections, inflammation, metabolic disorders/endocrine system function and neurological disorders.
45 cl, 1 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| TETRAHYDROPYRANYL AMINO-PYRROLOPYRIMIDINONE AND METHODS OF ITS USE | 2020 |
|
RU2747991C1 |
| COMPOSITIONS AND METHODS WHICH CAN BE USED FOR TREATING PROLIFERATIVE DISEASES | 2015 |
|
RU2711500C2 |
| HETEROCYCLIC COMPOUNDS AND THEIR APPLICATION | 2016 |
|
RU2744897C2 |
| 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND VARIANTS OF THEIR USE | 2018 |
|
RU2795850C2 |
| QUINAZOLINONE DERIVATIVE, A METHOD FOR PRODUCTION THEREOF, A PHARMACEUTICAL COMPOSITION AND USE THEREOF | 2017 |
|
RU2730500C2 |
| COMPOUND BASED ON PYRROLAMIDOPYRIDONE, METHOD OF ITS PREPARATION AND USE | 2020 |
|
RU2809596C2 |
| PURIFIED PYRROLOQUINOLINYL-PYRROLIDINE-2,5-DIONE COMPOSITIONS AND METHODS OF OBTAINING AND APPLICATION THEREOF | 2010 |
|
RU2556205C2 |
| POLYMORPHS OF KINASE INHIBITOR | 2012 |
|
RU2636588C2 |
| COMBINED THERAPY FOR CANCER TREATMENT | 2013 |
|
RU2699546C2 |
| COMPOUNDS FOR TREATMENT OF CANCER | 2015 |
|
RU2805949C2 |
